Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia

Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan25 enrolled

Overview

The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia

Objective:A few case reports on the use of aripiprazole in neuroleptic-induced tardive dyskinesia have demonstrated positive effects. However its effectiveness in treatment of TD was still inconclusive. The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia. Method: Subjects with pre-existing neuroleptic-induced tardive dyskinesia were chosen from Taoyuan psychiatric center. Patients recruited would be treated with aripiprazole for cross-titration with previous antipsychotics in 8 weeks. We use AIMS, SAS, \& BAS to assess the severity of TF and EPS. We record subjects' age, sex, and other factors which have influence at the treatment response. Subjects are assessed every two weeks in the first month and then monthly until six months.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dyskinesia, Drug-Induced

Interventions

aripiprazoleDRUG

Flexible dose: 5-30 mg/day

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Female patients must agree to prevent from being pregnant during trial periods * Meet psychotic disorder or mood disorder criteria of DSM-IV * Patients must have psychiatric diseases that need to use antipsychotics for a long time * They must meet DSM-IV research criteria for neuroleptics induce tardive dyskinesia * No clinical significant major systemic diseases * No special neurological diseases which would influence the assessment for EPS or TD * Mentality is better than mild mental retardation * Patients or .legal representatives agree to join in the research and sign informed consent. Exclusion Criteria: * Unstable major systemic diseases * Had neurological disorder influenced to EPS assessment * Substance abuse or dependence other then coffee or tobacco within 6 months before study

Locations (1)

Taoyuan Mental Hospital

Taoyuan District, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Total scores of AIMS

Time frame: The change from baseline to study endpoint

Secondary Outcomes

Total scores of PANSS

Time frame: The change from baseline to study endpoint

Total scores of SAS

Time frame: The change from baseline to study endpoint

Central Contacts

Chia-Hsiang Chan, M.D.

CONTACT

886-3-3698553 cscott1125@typc.doh.gov.tw

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.